Technology
Health
Biotechnology

Can Fite Biopharma

$1.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-8.15%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CANF and other stocks, options, ETFs, and crypto commission-free!

About

Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. Read More The company offers drugs for the treatment of Psoriasis, Rheumatic Arthritis, Glaucoma, Uveitis, Crohn's disease, Osteoathritis, Hepatitis C, and Liver Cancer. Can-Fite BioPharma was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach Tikva, Israel.

Employees
7
Headquarters
Petach Tikva, Tel Aviv
Founded
1994
Market Cap
24.50M
Price-Earnings Ratio
Dividend Yield
Average Volume
164.40K
High Today
$1.34
Low Today
$1.20
Open Price
$1.30
Volume
142.17K
52 Week High
$1.73
52 Week Low
$1.00

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2013 IPO

Earnings

-$0.06
-$0.03
$0.00
$0.03
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 25, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.